AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04111159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Subjects \< 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects \< 65 years old.
Study NCT00569166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paced breathing (15 min once daily, 6 breaths/min)
Description: Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
Study NCT03977506 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: On-road driving evaluation
Description: The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions.
Study NCT04607291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Service
Description: Receive Witness CARES services
Study NCT04607291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01593176 — intervention group
Intervention type: PROCEDURE
Intervention: Placement of RSA beads
Description: At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
Study NCT01695928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: 1000 impulses
Study NCT01695928 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ESWT placebo
Description: 0 impulses, acoustic effect
Study NCT02079701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal vaccine
Description: randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
Study NCT02079701 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01041443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetrahydrouridine
Description: Given IV
Study NCT03818399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBLOCADE
Description: SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
Study NCT02029365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autoquestionnary
Description: autoquestionnary completed during the consultation for infertility
Study NCT02029365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: semi-structured interview
Description: phone interview
Study NCT00934791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
Study NCT00934791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
Study NCT00934791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 750 mg twice daily
Study NCT00934791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone tapered to 5 mg/day by day 92
Study NCT02346955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM-24 (MK-6018)
Description: humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
Study NCT00569166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paced breathing (15 min twice daily, 6 breaths/min)
Description: Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
Study NCT00569166 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Paced breathing (10 min once daily, 14 breaths/min)
Description: Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
Study NCT00532350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAT370
Study NCT00532350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00532350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study NCT01041443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02346955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: 200 mg of Pembrolizumab by IV infusion
Study NCT01058018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: RVX000222 twice a day for 12 weeks
Study NCT02685839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent POWER Rehabilitation Cluster Machine
Study NCT02685839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: general physical therapy
Study NCT01041443 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study NCT01041443 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: Correlative studies
Study NCT04275609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI generated report
Description: After the endoscopic procedure, the physicians click the structured reporting button of computer to automatically complete the report through the structured diagnostic report generation system. The physicians only make minor corrections to the report.
Study NCT04275609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physicians writing report
Description: After the endoscopic procedure, the physicians writing the report in computer according the procedure.
Study NCT03035773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Plan Only
Description: Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
Study NCT03035773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Plan During a Visit
Description: Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
Study NCT03035773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Plan During a Visit with an Additional Visit
Description: Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
Study NCT01058018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 12 weeks
Study NCT01157208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet A
Description: Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
Study NCT01157208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet B
Description: Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
Study NCT03578484 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aesthetic assessment 3D breast scanning
Description: Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
Study NCT02708394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: atypical antipsychotic
Study NCT02708394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study NCT00927706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assistive technology updating and tune up intervention
Description: This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
Study NCT01582321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Description: The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
Study NCT01582321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: 0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
Study NCT04039646 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS treatment
Description: The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
Study NCT04039646 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ERAS treatment
Description: The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
Study NCT02182609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kit for the Preparation of 99mTc-rhAnnexin V-128
Description: Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
Study NCT03254277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: Intravenous infusion of 3BNC117-LS
Study NCT00599196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.
Study NCT01784809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia WORTH
Description: The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. \*\*\*To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation
Study NCT01784809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional WORTH
Description: The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
Study NCT01784809 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Promotion
Study NCT03254277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01928823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
Study NCT01928823 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: 12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
Study NCT01928823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Administered for three times (50mg, oral) directly after exposure
Study NCT03251586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oVEMP - infra-orbital electrode montage
Description: oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
Study NCT03251586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: oVEMP - belly-tendon electrode montage
Description: oVEMPs are short latency (\~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
Study NCT02916407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%.
Study NCT03414723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Pharmaceutical form: tablets~Route of administration: oral
Study NCT02916407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%.
Study NCT01697228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Study NCT01439074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Description: Dressing
Study NCT01439074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulphadiazine Ag cream
Description: A cream used on burnt areas.
Study NCT02834923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement Protocol for CTH (EE-CTH)
Description: EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
Study NCT02834923 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Connection to Health (CTH)
Description: CTH is a comprehensive SMS program that focuses on behavior change.
Study NCT00953680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium (+) hydrochlorothiazide (HCTZ)
Description: Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
Study NCT00953680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: Single dose losartan 100 mg tablet in one of two treatment periods.
Study NCT00953680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide (HCTZ)
Description: Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
Study NCT02193087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDV Liquid Formulation 1
Description: TDV Liquid Formulation 1 for subcutaneous injection
Study NCT02193087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDV Liquid Formulation 2
Description: TDV Liquid Formulation 2 for subcutaneous injection
Study NCT02193087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDV IDT Lyophilized
Description: TDV Lyophilized Formulation for subcutaneous injection
Study NCT01087710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical food with EPA and GLA, vitamins and minerals
Description: 1 8oz serving per day for 12 weeks
Study NCT01087710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical food minus EPA and GLA, antioxidant vitamins/minerals
Description: 1 8oz serving a day for 12 weeks
Study NCT01929291 — intervention group
Intervention type: BIOLOGICAL
Intervention: Boostrix
Description: Single intramuscular injection
Study NCT01929291 — intervention group
Intervention type: OTHER
Intervention: Safety data collection
Description: Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
Study NCT03311880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
Study NCT02193087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TDV liquid formulation placebo-matching solution for subcutaneous injection
Study NCT01596686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one of two possible colon preparation regimens
Description: Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate